## **Product** Data Sheet

# PF 05089771 tosylate

Cat. No.: HY-12883B CAS No.: 1430806-04-4

 $\label{eq:molecular-formula:} \textbf{Molecular Formula:} \qquad \textbf{C}_{25}\textbf{H}_{20}\textbf{C}\textbf{I}_{2}\textbf{F}\textbf{N}_{5}\textbf{O}_{6}\textbf{S}_{3}$ 

Molecular Weight: 672.56

Target: Sodium Channel

Pathway: Membrane Transporter/Ion Channel

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

### **BIOLOGICAL ACTIVITY**

Description	PF 05089771 tosylate is a potent, orally active and selective arylsulfonamide Na $_{\rm v}$ 1.7 inhibitor, with IC $_{50}$ values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNa $_{\rm v}$ 1.7, cynNa $_{\rm v}$ 1.7, dogNa $_{\rm v}$ 1.7, ratNa $_{\rm v}$ 1.7, and musNa $_{\rm v}$ 1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy [1][2].
IC <sub>50</sub> & Target	$ \text{IC50: } 11 \text{ nM (hNa}_{\text{v}}1.7), 12 \text{ nM (cynNa}_{\text{v}}1.7), 13 \text{ nM (dogNa}_{\text{v}}1.7), 171 \text{ nM (ratNa}_{\text{v}}1.7), 8 \text{ nM (musNa}_{\text{v}}1.7)^{[1][2]}. \\$
In Vitro	PF-05089771 is determined to be more than 1000-fold selective over tetrodotoxin-resistant (TTX-R) Na <sub>v</sub> 1.5 and Na <sub>v</sub> 1.8 channels (IC <sub>50</sub> s >10 $\mu$ M) and exhibited a range of selectivity over TTX-sensitive (TTX-S) channels (10-fold for Na <sub>v</sub> 1.2 to 900-fold for Na <sub>v</sub> 1.3 and Na <sub>v</sub> 1.4) <sup>[1]</sup> . PF-05089771 (30 nM) blocks the majority of TTX-S current (75.5 $\pm$ 10.5%, n = 5) whilst 100 nM resulted in complete block <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

- FEBS J. 2022 Jan 13.
- Front Pharmacol. 16 December 2021.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Alexandrou AJ, et al. Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release. PLoS One. 2016 Apr 6;11(4):e0152405.

[2]. Theile JW, et al. The Selective Nav1.7 Inhibitor, PF-05089771, Interacts Equivalently with Fast and Slow Inactivated Nav1.7 Channels. Mol Pharmacol. 2016 Nov;90(5):540-548.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com